Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rochelle Manning"'
Autor:
Susan L. McGovern, MD, PhD, Cody Wages, CMD, Andrew Dimmitt, RTT, Christopher Sanders, RTT, Deanna Martin, Matthew S. Ning, MD, Rochelle Manning, MSN, RN, Mayank Amin, CMD, X. Ronald Zhu, PhD, Steven J. Frank, MD, G. Brandon Gunn, MD
Publikováno v:
International Journal of Particle Therapy, Vol 7, Iss 1, Pp 54-57 (2020)
Externí odkaz:
https://doaj.org/article/d10727fcc97a44cd89a9c0b452279ac9
Autor:
Cody A. Wages, X. Ronald Zhu, Rochelle Manning, Matthew S. Ning, Susan L. McGovern, Steven J. Frank, Christopher Sanders, G. Brandon Gunn, Andrew Wilson Dimmitt, Deanna Martin, Mayank Amin
Publikováno v:
International Journal of Particle Therapy, Vol 7, Iss 1, Pp 54-57 (2020)
International Journal of Particle Therapy
International Journal of Particle Therapy
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
Autor:
Mehmet Fatih Okcu, Terri S. Armstrong, Elizabeth Vera-Bolanos, Yumei Cao, Melissa L. Bondy, Rochelle Manning, Renke Zhou, Mark R. Gilbert, Michael E. Scheurer
Publikováno v:
Neuro-Oncology. 11:825-832
A benefit of temozolomide (TMZ) is that myelotoxicity is uncommon. Recently, several small series have reported significant myelotoxicity resulting in treatment delays or death. The ability to predict risk of myelotoxicity may influence patient care.
Complementary and Alternative Medicine Use and Quality of Life in Patients with Primary Brain Tumors
Autor:
Rochelle Manning, Mark R. Gilbert, Geline Tamayo, Eva Lu Lee, Terri S. Armstrong, W. K. Alfred Yung, Marlene Z. Cohen, Sur J. Min, Kenneth R. Hess, Karen Baumgartner
Publikováno v:
Journal of Pain and Symptom Management. 32:148-154
This study explored the use of complementary and alternative medicine (CAM) approaches and their relationship with demographic and disease characteristics and quality of life (QOL) in the primary brain tumor (PBT) population. One hundred one PBT pati
Autor:
Mehmet Fatih Okcu, Rochelle Manning, Mark R. Gilbert, Elizabeth Vera, Melissa L. Bondy, Yumei Cao, Michael E. Scheurer, Terri Armstrong
Publikováno v:
Journal of Clinical Oncology. 26:9548-9548
9548 Background: A benefit of temozolomide (TMZ) is that myelosuppression (TOX) is uncommon. Recently, several small series report significant TOX resulting in treatment delays or even death in mal...